Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Tranquilizer Drugs Market

ID: MRFR/Pharma/20120-HCR
128 Pages
Nidhi Mandole
Last Updated: April 06, 2026

Tranquilizer Drugs Market Research Report Information By Major Tranquilizers (Phenothiazine Derivatives, Butyrophenones, Thioxanthene Derivatives, and Others), By Minor Tranquilizers (Benzodiazepine Derivatives, Propanediol Dicarbamate Derivatives, Cyclopyrrolone Derivatives, and Others) and By Region (North America, Europe, Asia-Pacific, and Rest of the World) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Tranquilizer Drugs Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Major Tranquilizers (USD Billion)
  49.     4.1.1 Phenothiazine Derivatives
  50.     4.1.2 Butyrophenones
  51.     4.1.3 Thioxanthene Derivatives
  52.     4.1.4 Others
  53.   4.2 Healthcare, BY Minor Tranquilizers (USD Billion)
  54.     4.2.1 Benzodiazepine Derivatives
  55.     4.2.2 Propanediol Dicarbamate Derivatives
  56.     4.2.3 Cyclopyrrolone Derivatives
  57.     4.2.4 Others
  58.   4.3 Healthcare, BY Region (USD Billion)
  59.     4.3.1 North America
  60.       4.3.1.1 US
  61.       4.3.1.2 Canada
  62.     4.3.2 Europe
  63.       4.3.2.1 Germany
  64.       4.3.2.2 UK
  65.       4.3.2.3 France
  66.       4.3.2.4 Russia
  67.       4.3.2.5 Italy
  68.       4.3.2.6 Spain
  69.       4.3.2.7 Rest of Europe
  70.     4.3.3 APAC
  71.       4.3.3.1 China
  72.       4.3.3.2 India
  73.       4.3.3.3 Japan
  74.       4.3.3.4 South Korea
  75.       4.3.3.5 Malaysia
  76.       4.3.3.6 Thailand
  77.       4.3.3.7 Indonesia
  78.       4.3.3.8 Rest of APAC
  79.     4.3.4 South America
  80.       4.3.4.1 Brazil
  81.       4.3.4.2 Mexico
  82.       4.3.4.3 Argentina
  83.       4.3.4.4 Rest of South America
  84.     4.3.5 MEA
  85.       4.3.5.1 GCC Countries
  86.       4.3.5.2 South Africa
  87.       4.3.5.3 Rest of MEA
  88. 5 SECTION V: COMPETITIVE ANALYSIS
  89.   5.1 Competitive Landscape
  90.     5.1.1 Overview
  91.     5.1.2 Competitive Analysis
  92.     5.1.3 Market share Analysis
  93.     5.1.4 Major Growth Strategy in the Healthcare
  94.     5.1.5 Competitive Benchmarking
  95.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  96.     5.1.7 Key developments and growth strategies
  97.       5.1.7.1 New Product Launch/Service Deployment
  98.       5.1.7.2 Merger & Acquisitions
  99.       5.1.7.3 Joint Ventures
  100.     5.1.8 Major Players Financial Matrix
  101.       5.1.8.1 Sales and Operating Income
  102.       5.1.8.2 Major Players R&D Expenditure. 2023
  103.   5.2 Company Profiles
  104.     5.2.1 Pfizer (US)
  105.       5.2.1.1 Financial Overview
  106.       5.2.1.2 Products Offered
  107.       5.2.1.3 Key Developments
  108.       5.2.1.4 SWOT Analysis
  109.       5.2.1.5 Key Strategies
  110.     5.2.2 Bristol-Myers Squibb (US)
  111.       5.2.2.1 Financial Overview
  112.       5.2.2.2 Products Offered
  113.       5.2.2.3 Key Developments
  114.       5.2.2.4 SWOT Analysis
  115.       5.2.2.5 Key Strategies
  116.     5.2.3 Roche (CH)
  117.       5.2.3.1 Financial Overview
  118.       5.2.3.2 Products Offered
  119.       5.2.3.3 Key Developments
  120.       5.2.3.4 SWOT Analysis
  121.       5.2.3.5 Key Strategies
  122.     5.2.4 Sanofi (FR)
  123.       5.2.4.1 Financial Overview
  124.       5.2.4.2 Products Offered
  125.       5.2.4.3 Key Developments
  126.       5.2.4.4 SWOT Analysis
  127.       5.2.4.5 Key Strategies
  128.     5.2.5 AstraZeneca (GB)
  129.       5.2.5.1 Financial Overview
  130.       5.2.5.2 Products Offered
  131.       5.2.5.3 Key Developments
  132.       5.2.5.4 SWOT Analysis
  133.       5.2.5.5 Key Strategies
  134.     5.2.6 Novartis (CH)
  135.       5.2.6.1 Financial Overview
  136.       5.2.6.2 Products Offered
  137.       5.2.6.3 Key Developments
  138.       5.2.6.4 SWOT Analysis
  139.       5.2.6.5 Key Strategies
  140.     5.2.7 Eli Lilly (US)
  141.       5.2.7.1 Financial Overview
  142.       5.2.7.2 Products Offered
  143.       5.2.7.3 Key Developments
  144.       5.2.7.4 SWOT Analysis
  145.       5.2.7.5 Key Strategies
  146.     5.2.8 Teva Pharmaceutical Industries (IL)
  147.       5.2.8.1 Financial Overview
  148.       5.2.8.2 Products Offered
  149.       5.2.8.3 Key Developments
  150.       5.2.8.4 SWOT Analysis
  151.       5.2.8.5 Key Strategies
  152.     5.2.9 Mylan (US)
  153.       5.2.9.1 Financial Overview
  154.       5.2.9.2 Products Offered
  155.       5.2.9.3 Key Developments
  156.       5.2.9.4 SWOT Analysis
  157.       5.2.9.5 Key Strategies
  158.   5.3 Appendix
  159.     5.3.1 References
  160.     5.3.2 Related Reports
  161. 6 LIST OF FIGURES
  162.   6.1 MARKET SYNOPSIS
  163.   6.2 NORTH AMERICA MARKET ANALYSIS
  164.   6.3 US MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  165.   6.4 US MARKET ANALYSIS BY MINOR TRANQUILIZERS
  166.   6.5 CANADA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  167.   6.6 CANADA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  168.   6.7 EUROPE MARKET ANALYSIS
  169.   6.8 GERMANY MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  170.   6.9 GERMANY MARKET ANALYSIS BY MINOR TRANQUILIZERS
  171.   6.10 UK MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  172.   6.11 UK MARKET ANALYSIS BY MINOR TRANQUILIZERS
  173.   6.12 FRANCE MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  174.   6.13 FRANCE MARKET ANALYSIS BY MINOR TRANQUILIZERS
  175.   6.14 RUSSIA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  176.   6.15 RUSSIA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  177.   6.16 ITALY MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  178.   6.17 ITALY MARKET ANALYSIS BY MINOR TRANQUILIZERS
  179.   6.18 SPAIN MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  180.   6.19 SPAIN MARKET ANALYSIS BY MINOR TRANQUILIZERS
  181.   6.20 REST OF EUROPE MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  182.   6.21 REST OF EUROPE MARKET ANALYSIS BY MINOR TRANQUILIZERS
  183.   6.22 APAC MARKET ANALYSIS
  184.   6.23 CHINA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  185.   6.24 CHINA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  186.   6.25 INDIA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  187.   6.26 INDIA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  188.   6.27 JAPAN MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  189.   6.28 JAPAN MARKET ANALYSIS BY MINOR TRANQUILIZERS
  190.   6.29 SOUTH KOREA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  191.   6.30 SOUTH KOREA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  192.   6.31 MALAYSIA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  193.   6.32 MALAYSIA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  194.   6.33 THAILAND MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  195.   6.34 THAILAND MARKET ANALYSIS BY MINOR TRANQUILIZERS
  196.   6.35 INDONESIA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  197.   6.36 INDONESIA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  198.   6.37 REST OF APAC MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  199.   6.38 REST OF APAC MARKET ANALYSIS BY MINOR TRANQUILIZERS
  200.   6.39 SOUTH AMERICA MARKET ANALYSIS
  201.   6.40 BRAZIL MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  202.   6.41 BRAZIL MARKET ANALYSIS BY MINOR TRANQUILIZERS
  203.   6.42 MEXICO MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  204.   6.43 MEXICO MARKET ANALYSIS BY MINOR TRANQUILIZERS
  205.   6.44 ARGENTINA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  206.   6.45 ARGENTINA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  207.   6.46 REST OF SOUTH AMERICA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  208.   6.47 REST OF SOUTH AMERICA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  209.   6.48 MEA MARKET ANALYSIS
  210.   6.49 GCC COUNTRIES MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  211.   6.50 GCC COUNTRIES MARKET ANALYSIS BY MINOR TRANQUILIZERS
  212.   6.51 SOUTH AFRICA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  213.   6.52 SOUTH AFRICA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  214.   6.53 REST OF MEA MARKET ANALYSIS BY MAJOR TRANQUILIZERS
  215.   6.54 REST OF MEA MARKET ANALYSIS BY MINOR TRANQUILIZERS
  216.   6.55 KEY BUYING CRITERIA OF HEALTHCARE
  217.   6.56 RESEARCH PROCESS OF MRFR
  218.   6.57 DRO ANALYSIS OF HEALTHCARE
  219.   6.58 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  220.   6.59 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  221.   6.60 SUPPLY / VALUE CHAIN: HEALTHCARE
  222.   6.61 HEALTHCARE, BY MAJOR TRANQUILIZERS, 2024 (% SHARE)
  223.   6.62 HEALTHCARE, BY MAJOR TRANQUILIZERS, 2024 TO 2035 (USD Billion)
  224.   6.63 HEALTHCARE, BY MINOR TRANQUILIZERS, 2024 (% SHARE)
  225.   6.64 HEALTHCARE, BY MINOR TRANQUILIZERS, 2024 TO 2035 (USD Billion)
  226.   6.65 BENCHMARKING OF MAJOR COMPETITORS
  227. 7 LIST OF TABLES
  228.   7.1 LIST OF ASSUMPTIONS
  229.     7.1.1
  230.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  231.     7.2.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  232.     7.2.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  233.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  234.     7.3.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  235.     7.3.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  236.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  237.     7.4.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  238.     7.4.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  239.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  240.     7.5.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  241.     7.5.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  242.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  243.     7.6.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  244.     7.6.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  245.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  246.     7.7.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  247.     7.7.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  248.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  249.     7.8.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  250.     7.8.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  251.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  252.     7.9.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  253.     7.9.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  254.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  255.     7.10.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  256.     7.10.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  257.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  258.     7.11.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  259.     7.11.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  260.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  261.     7.12.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  262.     7.12.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  263.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  264.     7.13.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  265.     7.13.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  266.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  267.     7.14.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  268.     7.14.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  269.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  270.     7.15.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  271.     7.15.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  272.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  273.     7.16.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  274.     7.16.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  275.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  276.     7.17.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  277.     7.17.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  278.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  279.     7.18.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  280.     7.18.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  281.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  282.     7.19.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  283.     7.19.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  284.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  285.     7.20.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  286.     7.20.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  287.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  288.     7.21.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  289.     7.21.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  290.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  291.     7.22.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  292.     7.22.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  293.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  294.     7.23.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  295.     7.23.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  296.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  297.     7.24.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  298.     7.24.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  299.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  300.     7.25.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  301.     7.25.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  302.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  303.     7.26.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  304.     7.26.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  305.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  306.     7.27.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  307.     7.27.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  308.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  309.     7.28.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  310.     7.28.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  311.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  312.     7.29.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  313.     7.29.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  314.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  315.     7.30.1 BY MAJOR TRANQUILIZERS, 2025-2035 (USD Billion)
  316.     7.30.2 BY MINOR TRANQUILIZERS, 2025-2035 (USD Billion)
  317.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  318.     7.31.1
  319.   7.32 ACQUISITION/PARTNERSHIP
  320.     7.32.1

Healthcare Market Segmentation

Healthcare By Major Tranquilizers (USD Billion, 2025-2035)

  • Phenothiazine Derivatives
  • Butyrophenones
  • Thioxanthene Derivatives
  • Others

Healthcare By Minor Tranquilizers (USD Billion, 2025-2035)

  • Benzodiazepine Derivatives
  • Propanediol Dicarbamate Derivatives
  • Cyclopyrrolone Derivatives
  • Others

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions